KLDO

SC 13G/A - Kaleido Biosciences, Inc. (0001751299) (Subject)

15-12B - Kaleido Biosciences, Inc. (0001751299) (Filer)

EFFECT - Kaleido Biosciences, Inc. (0001751299) (Filer)

S-8 POS - Kaleido Biosciences, Inc. (0001751299) (Filer)

S-8 POS - Kaleido Biosciences, Inc. (0001751299) (Filer)

S-8 POS - Kaleido Biosciences, Inc. (0001751299) (Filer)

POS AM - Kaleido Biosciences, Inc. (0001751299) (Filer)

25 - Kaleido Biosciences, Inc. (0001751299) (Filer)

Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting season. Lyra Therapeutics, Inc. (NASDAQ:LYRA) was among the biggest gainers of the week following the completion of a $100.5 million private placement. Sierra Oncology, Inc. (NASDAQ:SRRA) also advanced strongly after it announced a deal to be acquired by GlaxoSmithKline plc (NYSE:GSK) for $1.9 billion. Meanwhile, Kaleido Biosciences, Inc. (NASDAQ:KLDO) plunged after disclosing in a filing that it is shuttering operations. The microbiome therapeutic-focused biopharma was facing a cash crunch

Gainers Kaleido Biosciences (NASDAQ:KLDO) stock increased by 10.3% to $0.32 during Thursday's after-market session. Today's trading volume for this security ended up closing at 14.2 million shares, which is 369.4 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $13.6 million. NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares moved upwards by 9.28% to $0.95. At the close, NeuroBo Pharmaceuticals's trading volume reached 232.9K shares. This is 119.9% of its average volume over the last 100 days. The company's market cap stands at $25.3 million. ASLAN Pharma (NASDAQ:ASLN) shares rose 9.14% to $0.82. The market value of their outstanding shar

Gainers Kaleido Biosciences (NASDAQ:KLDO) stock increased by 24.9% to $0.38 during Thursday's regular session. As of 13:30 EST, Kaleido Biosciences's stock is trading at a volume of 53.0 million, which is 1374.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $16.0 million. Verastem (NASDAQ:VSTM) stock moved upwards by 21.89% to $1.86. As of 13:30 EST, Verastem's stock is trading at a volume of 24.4 million, which is 1316.4% of its average full-day volume over the last 100 days. The company's market cap stands at $347.5 million. Trevi Therapeutics (NASDAQ:TRVI) shares rose 19.06% to $3.31. The current volume of 2.2 million shares

Today's 5 Stock Ideas: Twitter (TWTR) - Shares were up ~6% near the $49 level following news Elon Musk made an offer to buy all of the company at $54.20 per share in cash. Analysts were mixed on the news; a Wedbush analyst, Dan Ives, was optimistic the offer would be accepted while another analyst voiced concern about Elon Musk walking away from the company if his offer was rejected. Li Auto (LI) - A potential sympathy play following a report the CEO of peer in the Chinese electric vehicle space, XPeng (XPEV), warned all Chinese vehicle factories may have to stop production in May if supply chain disruption continues. Safe-T Group (SFET) - A play on cybersecurity. Stocks

Gainers Kaleido Biosciences (NASDAQ:KLDO) shares moved upwards by 105.3% to $0.35 during Wednesday's regular session. Kaleido Biosciences's stock is trading at a volume of 170.1 million shares as of 13:30 EST. This is 20116.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $15.0 million. Antares Pharma (NASDAQ:ATRS) shares increased by 49.19% to $5.58. As of 13:30 EST, this security is trading at a volume of 105.0 million shares, making up 13080.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $949.1 million. Sierra Oncology (NASDAQ:SRRA) stock rose 38.62% to $54.78. Trad

Gainers Alzamend Neuro (NASDAQ:ALZN) shares rose 19.6% to $1.22 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 223.2K shares, which is 17.9 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $109.9 million. Agile Therapeutics (NASDAQ:AGRX) shares increased by 18.74% to $0.22. At the close, Agile Therapeutics's trading volume reached 6.5 million shares. This is 341.7% of its average volume over the last 100 days. The company's market cap stands at $30.0 million. Biophytis (NASDAQ:BPTS) shares moved upwards by 15.55% to $2.08. The market value of their outstanding shares is at $30.6 mi

  Gainers Phio Pharma (NASDAQ:PHIO) shares increased by 46.7% to $1.33 during Friday's regular session. As of 13:31 EST, Phio Pharma's stock is trading at a volume of 9.3 million, which is 1477.4% of its average full-day volume over the last 100 days. The company's market cap stands at $18.0 million. Exicure (NASDAQ:XCUR) shares rose 21.72% to $0.25. Trading volume for this security as of 13:31 EST is 50.6 million, which is 399.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $31.2 million. Lyra Therapeutics (NASDAQ:LYRA) shares moved upwards by 16.31% to $5.03. Trading volume for Lyra Therapeutics's stock is 4.7 million as of

    During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was U.S. Bancorp (NYSE:USB). Vallon Pharmaceuticals (NASDAQ:VLON) was the smallest company in terms of market cap to set a new 52-week low. Kaleido Biosciences (NASDAQ:KLDO) made the largest move down on the session, with shares plummeting 75.78% to reach its 52-week low. Blackrock Muniholdings (NYSE:MFL) was the biggest winner of the bunch, with shares actually trading up 0.0% after it rebounded from its new 52-week low. The following stocks set new 52-week lows on Friday: U.S. Bancorp (NYSE:USB)

Kaleido Biosciences Inc (NASDAQ:KLDO) has delivered formal notice to voluntarily delist its common stock from NASDAQ as the Company will stop all operations. The Company expects to file a Form 25 with the Securities and Exchange Commission by April 18 to effect the voluntary delisting effective by April 28. The Board of Directors voted to immediately wind down and cease all of the Company’s ongoing operations.  Related: Kaleido Halts Upcoming Phase 2 COPD Trial, Piper Sandler Cuts Price Target. In connection with the cessation of activities, the employment of all of the Company’s remaining employees was terminated effective immediately.  As previously announced, the Company had initia